Infectious diseases remain a serious and now re-emerging threat to human life, contributing to over ten million deaths per year. Treatment of major infectious diseases with antibacterial agents creates an ongoing and escalating public health issue that currently leads to more problems than solutions. By processes of adaptation and survival, bacteria consistently develop mechanisms to overcome the effects of the newest and most potent antibacterial compounds. Simultaneously, progressively fewer antibacterial agents are being developed by pharmaceutical and biotechnology companies. Although this dilemma is an inherent trade-off and has no imminent resolution, the most prudent paradigm to pursue is the judicious use of antibacterial agents in the most limited way possible to attain the desired treatment results. One straightforward approach to antimicrobial stewardship is to use a single agent as opposed to combination therapy, so as to subject bacteria to lower total antibiotic exposure whenever feasible. This article reviews current trends in antibacterial drug development and describes a context for adherence to monotherapy with newer agents.
I N T R O D U C T I O N
A potential 'post-antibiotic era' is threatening present and future medical advances. According to the WHO, there is a global risk of creating an environment similar to that of the pre-antibiotic era (i.e. before the middle of the 20th century), when deaths from infectious diseases were much more prevalent than they are currently, and modern implant and transplant surgery was impossible because of the risk of infection. Emergence of antimicrobial resistance is a natural phenomenon that is caused largely by antimicrobial use (and misuse). There is a global pandemic of resistant organisms that requires changes in how we address the problem [1] . In parallel with escalating resistance, the rate of development of new antimicrobial agents is declining, while rates of morbidity and mortality, and the costs associated with suboptimal treatment of infections caused by resistant organisms, are rising [2] . The combination of the current worldwide increase in resistant bacteria and the downward trend in the development of new antibiotics has serious health and economic implications [3] [4] [5] . Resistant bacteria dramatically reduce the possibility of treating infectious diseases effectively, increasing the risk of complications and fatal outcomes.
Indeed, the pipelines of the world's 15 largest pharmaceutical companies reflect a notable decline in the number of new antimicrobial agents under development and recently introduced. A survey by Spellberg et al. found that nine new antibacterial agents were introduced between 1998 and 2003, a drop from 16 such agents introduced between 1983 and 1987 (the first period for which the authors obtained data), with a steady decline during the intervening years up to the present [5] . Tigecycline, the first of the glycylcyclines, a new class of semisynthetic tetracyclines, was introduced in 2005, giving a current total of ten new antibacterials in the last decade; most, tigecycline included, represent extensions of an existing class of compounds. The authors contrasted this with the current trend in the number of new molecular entities (NMEs) in other drug classes being developed by the same companies, citing public disclosures of 23 NMEs for depression and anxiety, eight for bladder hyperactivity, and seven for osteoporosis, in contrast to only five antibacterial NMEs. Similarly, the world's seven largest biotechnology companies reported having a total 52 NMEs in development for indications in the areas of oncology, inflammation ⁄ immunomodulation and metabolism ⁄ endocrinology, but only one for antibacterial therapy [5] . The challenge of new antimicrobial development is one of the issues addressed by the recent Infectious Diseases Society of America (IDSA) policy document on antibiotic resistance [1] .
As few new antibacterials are being developed, the global need for a cooperative effort to ensure their appropriate use is increasing, with the objective of reducing the emergence of resistance. There is a need in the drug development process for a comprehensive approach that works in concert with health, education, economic and industrial policies. Containment of antibiotic resistance will depend on coordinated interventions to optimize antibiotic consumption. The current rising trends in resistance to antimicrobial agents suggest that the real problems are still ahead of us [2] .
In the interim, judicious use of existing antibacterials is paramount, but how to achieve this practically is unclear. It is realistic to hypothesize that the fewer antibacterials used the better, with less exposure to antimicrobials limiting the opportunity for microbes to develop resistance to these critical agents. Put another way, the fewer antibacterials used, the less the selection pressure on organisms that might develop resistance to multiple agents when used together. However, the use of fewer antimicrobial agents is not acceptable if it is accompanied by worse therapeutic outcomes.
Conceptually, the efficacy of monotherapy must be proven, as was done by a meta-analysis of randomized, controlled studies in a report by Bliziotis et al. [6] . They showed that rates of treatment failure attributable to the emergence of resistance, the development of superinfection or overall disease mortality did not differ significantly between b-lactam monotherapy and combination regimens containing a b-lactam and an aminoglycoside. Although generalization is probably unwise, the concept of monotherapy could become one practical pillar of antimicrobial stewardship, involving only one antimicrobial agent whenever possible while still covering the breadth of likely infecting pathogens.
The goals of this article are to: (i) discuss the antibiotics currently available for initial therapy; (ii) summarize the mechanisms of resistance to antimicrobials; and (iii) describe the microbiological and clinical profile of tigecycline, the first in a new group of broad-spectrum agents, the glycylcyclines, which provides a new, practical opportunity for increased use of monotherapy in the seriously ill patient.
A V A I L A B L E A G E N T S A N D T R E A T M E N T G U I D E L I N E S
Since the discovery and development of antimicrobial agents in the 20th century, many novel agents have become available, including penicillins, carbapenems, b-lactam-b-lactamase inhibitor combinations, extended-spectrum cephalosporins, aminoglycosides, monobactams, oxazolidinones, fluoroquinolones, macrolides, and tetracyclines [7, 8] .
Many of these drugs have provided extendedspectrum anti-Gram-positive and anti-Gram-negative activity, but despite the availability of these agents, resistance continues to disseminate among common pathogens (e.g. Staphylococcus aureus), while pathogens with new types of resistance emerge and spread (e.g. CTX-M-producing Escherichia coli and carbapenemase-producing Klebsiella pneumoniae strains).
Because prevalence patterns of resistant organisms vary widely and change continually, regional, national and local resistance must be considered in the selection of appropriate antibacterials to combat specific pathogens [3, 4] . Accordingly, the appropriate use of both older and newer agents is recommended through treatment guidelines that address antibacterial use by geographical region and type of infection. Guidelines for antibacterial use are most effective when they are evidence-based and focus on practical recommendations that remain up to date through ongoing monitoring of published clinical studies. They should also focus on the level of risk for the individual patient, which typically is different for healthcare-associated and community-acquired infections.
In the USA, the IDSA and the Surgical Infection Society (SIS) regularly update guidelines addressing the diagnosis and management of skin and soft tissue infections [8] and intra-abdominal infections [7, 9] . Tables 1 and 2 summarize the suggested available antibacterials for initial treatment of the most common of these infections as determined by the IDSA. Additionally, current SIS guidelines recommend ampicillin-sulbactam, cefotetan, cefoxitin, ertapenem, imipenem-cilastatin, meropenem, piperacillin-tazobactam and ticarcillin-clavulanic acid as single agents. For combination therapy, an aminoglycoside (amikacin, gentamicin, netilmicin, or tobramycin) plus an anti-anaerobe agent (clindamycin or metronidazole; the latter is preferred) can be considered, as well as aztreonam plus clindamycin, cefuroxime plus metronidazole, ciprofloxacin plus metronidazole, or a third ⁄ fourth-generation cephalosporin (cefepime, cefotaxime, ceftazidime, ceftizoxime, or ceftriaxone) with an anti-anaerobe drug for treatment of intra-abdominal infection.
In discussing the addition of a second agent, emphasis is placed upon achieving coverage of anaerobes. These guidelines highlight the in vitro activity afforded by carbapenems against routine isolates of Enterococcus spp. Although they do not find a justification for routine coverage of enterococci in community-acquired intra-abdominal infections, the current guidelines indicate the importance of such initial therapy for the higherrisk patient with an infection of suspected healthcare-associated origin [7] .
Tellado et al. [10] have published the Spanish Guidelines under the auspices of the Sociedad Españ ola de Quimioterapia and other Spanish surgical and infectious disease societies. These authors summarize appropriate initial treatment of intra-abdominal infections in light of IDSA, SIS and other published guidelines, including those of the Societé Française d'Anesthésie et de Réan-imation [11] , and the Consejo Europeo. Table 3 summarizes the activity profiles of currently available antibacterials published in the Spanish Guidelines.
M E C H A N I S M S O F A C T I O N A N D R E S I S T A N C E
Antibacterial agents prevent bacterial growth by disrupting the function of a wide variety of molecular targets located within bacteria and at the cell surface [12] . Fig. 1 summarizes the mechanisms of action of the most commonly used antibacterials. The penicillins, cephalosporins and carbapenems all target cell wall synthesis by inhibiting the transpeptidases required for peptidoglycan formation and cross-linking in the cell wall. Examples of drug target site modifications occurring in drug-resistant bacteria include penicillin-binding protein alterations that confer resistance to the b-lactam antibiotics and DNA gyrase mutations that alter the effectiveness of the fluoroquinolones. Enzymatic degradation of antibiotics is a mechanism that is usually associated with Gram-negative bacteria, and in the case of b-lactam resistance, it is due to b-lactamase production.
The fluoroquinolones block DNA synthesis by inhibiting DNA gyrase and topoisomerase IV, which are responsible for the DNA folding and supercoiling required for replication. Glycopeptide antibiotics (e.g. vancomycin) form complexes with the peptidoglycan that prevent binding of the transpeptidases that are responsible for terminal cross-linking. Metronidazole causes DNA damage that ultimately leads to cell death. The sulphonamides, trimethoprim-sulphamethoxazole and iclaprim (discussed elsewhere in this issue) block the metabolism of bacteria by inhibiting the enzymes needed for the synthesis of folic acid.
Many antibiotics, including the aminoglycosides, macrolides, oxazolidinones, streptogramins, lincosamides, and tetracyclines, interact with bacterial ribosomes at various sites to inhibit protein synthesis. In particular, the tetracyclines and glycylcyclines bind to the 30S subunit to inhibit binding of aminoacyl-tRNA to the A site of the ribosome and prevent the transfer of amino acids to newly forming protein chains (Fig. 1 ). Glycylcyclines are a new class of semisynthetic tetracyclines developed with the intention of circumventing both efflux-and target modification-mediated resistance to tetracyclines [12] . Bacteria that have developed tetracycline resistance have commonly acquired the ability to protect the bacterial target (the ribosome) or to produce efflux pumps that extrude the drug molecule from the cell; both mechanisms are evaded by tigecycline, the first glycylcycline, due to a bulky substituent. Thus, the diverse resistance mechanisms affecting the antimicrobial agents described should not have an effect on tigecycline, indicating that cross-resistance to this new agent, due to these mechanisms, should not be expected in otherwise multidrug-resistant bacteria.
S E L E C T I O N O F E M P I R I C A L A N T I M I C R O B I A L T H E R A P Y
Several decisions are important in selecting initial antimicrobial therapy, most importantly in surmising what the likely infecting pathogen is (based on the clinical presentation) and in choosing the adequate regimen on the basis of knowledge of the local antibiotic susceptibility of the expected pathogen, as well as of the pharmacokinetics of the chosen therapeutic agent. Other ancillary factors can also impact on the overall choice of antimicrobial therapy. These include ease of drug administration [13] , potential adverse events, the complex dosing schedules necessary with combination therapy, which can carry an increased risk of drug interactions, the need to monitor blood levels of some agents, complicated dosing adjustments in selected patients with renal disease or hepatic dysfunction, and treatment cost [6] . However, it is important to understand that the most critical aspect of therapy leading to a positive clinical outcome is early treatment with an effective agent.
The role of monotherapy
The intuitive benefit of monotherapy is that it subjects bacteria to less exposure to antimicrobial agents than combination therapy and thus might lead to a slowing of resistance development. Additional benefits include less complexity of drug administration and typically a lower overall therapeutic cost. Clinical evidence supports the hypothesis that certain antibacterials used as monotherapy are as efficacious as regimens that involve the addition of one or more drugs. As noted earlier, a meta-analysis by Bliziotis et al. [6] , incorporating eight studies published between 1983 and 1995, revealed that b-lactam monotherapy was not associated with a greater emergence Another study, by Cometta et al., found that the addition of vancomycin therapy did not improve the time to defervescence or lower mortality in piperacillin-tazobactam-treated, persistently febrile neutropenic patients with cancer ( Fig. 2) [14] . The outcome of this prospective, randomized, double-blind, multicentre trial (34 centres of the EORTC-IATG), which included adults and children (aged ‡2 years) in Europe, the Middle East and North America, and had as a primary objective the assessment of whether or not the addition of a glycopeptide would reduce the time to defervescence in neutropenic patients who had persistent fever, was that there was no benefit over monotherapy.
T I G E C Y C L I N E : A N E W M O N O T H E R A P Y O P T I O N
Tigecycline (Wyeth, formerly GAR-936) is the first glycylcycline antibacterial agent to be available for clinical use. It was approved for use by the US Food and Drug Administration (FDA) in June 2005, and is the first new tetracycline analogue since the introduction of minocycline over 30 years ago [15] [16] [17] . The chemical structures of tetracycline, minocycline and tigecycline are shown in Fig. 3 . As a glycylamido derivative of minocycline [16, 17] , tigecycline binds to the 30S ribosomal subunit [16] [17] [18] . Tigecycline possesses an expanded spectrum of in vitro activity [17] , and overcomes tetracycline resistance by retaining the ability to bind to bacterial ribosomes that are protected by the Tet(M) protein, a mechanism that compromises all available tetracyclines [16] [17] [18] . Tigecycline also evades the Tet(A-E) efflux pumps, which account for most of the acquired resistance to tetracycline and minocycline in Enterobacteriaceae and Acinetobacter spp., as well as the Tet(K) pumps, which occur widely in staphylococci and confer resistance to tetracycline, although not to minocycline or doxycycline [16] . It has been shown that overproduction of the AcrAB multidrug efflux pump is probably a key factor leading to decreased tigecycline susceptibility when found in E. coli [19] .
Summary of in vitro activity
The results of the Tigecycline Evaluation and Surveillance Trial (TEST) in vitro study published by Hoban et al. [20] demonstrated that tigecycline is highly active against the majority of community-and healthcare-associated Gram-positive bacterial isolates. [21] . Similarly, although the numbers of isolates were smaller, 100% of the vancomycinresistant enterococcal isolates tested were susceptible to tigecycline. The TEST study also showed that tigecycline is highly active against Enterobacteriaceae, with activity similar to that of imipenem, and superior to that of numerous comparator agents, including ceftazidime and piperacillintazobactam (Table 5) . In other studies, tigecycline has demonstrated potent activity against Enterobacteriaceae, including extended-spectrum b-lactamase (ESBL)-, CTX-M-9-, SHV-producing E. coli [22, 23] and non-ESBL-producing K. pneumoniae [24] . Of note, Morosini et al. reported the in vitro activity of nine antibacterials against organisms with ESBL phenotypes characteristically associated with cross-resistance to other drug classes, and tigecycline and imipenem demonstrated similar activity against 285 ESBL-producing isolates from Spain (community and healthcare-associated Enterobacteriacea), exhibiting the lowest MIC 90 values (1.0 mg ⁄ L for tigecycline; 0.5 g ⁄ L for imipenem) of all agents tested (Table 6 ) [22] . The most commonly observed ESBLs were CTX-M-type enzymes (in >58% of both nosocomial and community isolates), and these were typically associated with cross-resistance to other antimicrobials, including aminoglycosides, fluoroquinolones, sulphonamides, and trimethoprim [22] .
An additional study conducted in Spain by Sorló zano et al., which used the breakpoint for tigecycline established by the FDA in 2005 for Enterobacteriaceae (MIC £2 mg ⁄ L), demonstrated that 100% of the ESBL-producing E. coli isolates were susceptible to tigecycline, and all of the isolates tested were inhibited by a concentration of £0.75 mg ⁄ L, regardless of the type of ESBL produced [23] . Although the long-term success of the strategy of using a new agent (e.g. tigecycline) for monotherapy will depend on clinical response, the initial blinded, randomized clinical trials showing the efficacy of tigecycline are encouraging [25, 26] .
Antibacterial resistance is often thought to begin in intensive-care units in patients with infection, and resistance among specific Gram- negative non-fermenters is viewed as a particular threat in this setting. Tigecycline is active (in vitro) against many non-fermenting Gram-negative bacteria (e.g. Acinetobacter spp. and Stenotrophomonas maltophilia), with the important exception of Pseudomonas aeruginosa. The recent publication of a systematic review and an open-label trial suggests that the in vitro activity of tigecycline translates into effective clinical response when this new agent is used in the therapy of serious infection due to these difficult-to-treat pathogens [27, 28] . In a large in vitro trial, Sader et al. [29] tested the susceptibility of 9093 non-fermenting Gram-negative isolates from bloodstream (68.5%), respiratory tract (13.6%), skin ⁄ soft tissue (5.5%) and urinary tract (2.0%) infections in intensive-care unit patients between 2000 and 2004. Tigecycline and trimethoprim-sulphamethoxazole were the most active against Acinetobacter spp. and Stenotrophomonas maltophilia among all the antibacterials tested (MIC 90 £2 mg ⁄ L). As expected, tigecycline proved to be ineffective against P. aeruginosa strains (MIC 90 16 mg ⁄ L), although 93.3% of 171 Acinetobacter baumannii isolates tested were susceptible to tigecycline (susceptibility breakpoint of £2 mg ⁄ L) [29] . Also reported was the alarming finding of a high level of vancomycin resistance among enterococci, ESBL-mediated b-lactam resistance, fluoroquinolone resistance among Enterobacteriaceae, and carbapenem resistance among P. aeruginosa and Acinetobacter spp. Tigecycline showed consistently good activity against these organisms with the indicated resistance phenotypes, except against P. aeruginosa [24] .
Waites et al. reported additional data from the TEST program in 2006 [24] that demonstrate the efficacy of tigecycline against A. baumannii as well as ESBL-producing and non-producing K. pneumoniae. Susceptibility was determined according to the testing methods and interpretive criteria of the CLSI. For tigecycline, the FDAapproved criteria were applied to those organisms that are listed in the package insert. Among a total of 1460 strains of K. pneumoniae screened, 126 (8.6%) were confirmed ESBL producers. Tigecycline activity was unaffected by ESBL production, and was the only compound to which more than 90% of ESBL-producing isolates were susceptible. Livermore [16] points out that many carbapenemase-producing A. baumannii isolates are resistant to all available agents except the polymyxins, which, in addition to their in vitro antibacterial activity, have the drawbacks of toxicity and poor penetration into respiratory secretions. Because tigecycline is active against Adapted from reference [20] .
most carbapenemase-producing A. baumannii strains (MICs £2 mg ⁄ L), it may provide a useful alternative or adjunct to polymyxins, with a comparable potency [29] .
Pharmacokinetics and dosing
In three phase 1 studies of single and multiple doses ranging from 12.5 to 300 mg in healthy subjects, tigecycline exhibited linear pharmacokinetics at steady state, a large apparent volume of distribution (7-10 L ⁄ kg), and a long elimination half-life (t 1 ⁄ 2 ), ranging from 37 to 67 h [30] . Systemic clearance ranged from 0.2 to 0.3 L ⁄ h ⁄ kg. Food intake afforded a higher tolerability of a single dose (between 100 and 200 mg), but the duration of infusion did not affect tolerability. Nausea and vomiting were the most common side effects observed in these studies, and appeared to be dose-related.
These findings confirm those of earlier tigecycline pharmacokinetic studies, which have shown that multiple doses of a 30-min infusion of 50 mg of tigecycline every 12 h produce a linear pharmacokinetic course, with a maximum plasma concentration (C max ) of 0.87 mg ⁄ L, whereas a single 100-mg dose of tigecycline produces a terminal t 1 ⁄ 2 of 27 h. The minimum serum concentration (C min ) observed with tigecycline is 0.13 mg ⁄ L, and the area under the serum concentration-time curve from 0 to 24 h (AUC 0-24 h ) is 4.7 mg h ⁄ L. The average steady-state apparent volume of distribution (V ss ) is 639 L, which indicates that tigecycline has extensive distribution beyond the plasma volume, with deposition into human tissues [31] [32] [33] . Tigecycline skin tissue penetration has been demonstrated in a study by Sun et al.; they used the ratio between the tigecycline area under the blister fluid concentration-time curve (AUC 0-12 h ) in experimentally induced blisters and the serum equivalent after a total of seven 50-mg intravenous doses in healthy subjects, and found a mean rate of tigecycline penetration into the blister fluid of 74% [34] .
A single-dose (100 mg, intravenous) study by Rodvold et al. in patients undergoing elective surgery or medical procedures yielding tissue for drug extraction found that the concentration of tigecycline exceeded that found in serum 23-fold in gall bladder tissue, two-fold in lung tissue, and 2.6-fold in colon tissue [35] . Another recent study, by Ji et al., demonstrates the importance of the assay technique, as it was shown that Adapted from reference [22] . Clinical cure rates in complicated skin and soft tissue infection (cSSTI) and complicated intraabdominal infection (cIAI) phase 3 studies of tigecycline and comparators. Adapted from references [25, 26] .
tigecycline concentration in bone exceeded that in serum several-fold when careful drug extraction was performed [36] . The standard dosage of tigecycline is 100 mg administered intravenously, followed by 50 mg every 12 h; importantly, no dosing adjustments are needed in cases of renal impairment or mild ⁄ moderate hepatic disease [33] . Also, the pharmacokinetic parameters of tigecycline do not differ significantly between sexes, or across age groups (healthy subjects aged 18-50, 55-75 and >75 years); therefore, no dosage adjustment is necessary according to age or sex [37] , thus simplifying its use. Tigecycline is not extensively metabolized, and is eliminated primarily by the biliary-faecal route. In healthy male volunteers receiving [
14 C]tigecycline, tigecycline was the primary 14 C-labelled material recovered in urine and faeces, but a glucuronide, an N-acetyl metabolite and a tigecycline epimer (each at no more than 10% of the administered dose) were also present. The recovery of total radioactivity in faeces and urine following administration of [
14 C]tigecycline indicates that 59% of the dose is eliminated by biliaryfaecal excretion, and 33% is excreted in the urine, with approximately 22% of the total dose being excreted as unchanged tigecycline in urine [38] .
In vitro studies in human liver microsomes indicate that tigecycline is not metabolized by, and does not inhibit or induce, cytochrome enzymes, including cytochrome P450 isoforms 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4. Thus, it has a low potential for interactions with drugs that inhibit or induce the activity of these cytochrome P450 isoforms [33] . The only cautionary note regarding drug-drug interactions is based on phase 1 safety data that show increases in warfarin C max and AUC when this drug is administered with tigecycline. However, warfarin did not affect the pharmacokinetic profile of tigecycline [33] .
Clinical implications of pharmacodynamic measures
One pharmacodynamic variable affecting the broad-spectrum efficacy of an antibacterial agent is the measurable ratio between pharmacokinetic parameters and bacterial susceptibility. Ambrose et al. recently reported that the AUC 0-24 ⁄ MIC ratio is the appropriate clinically derived pharmacokinetic-pharmacodynamic target for tigecycline (in contrast to time above the MIC, which is more applicable to b-lactams), citing a clinically derived exposure-response AUC 0-24 ⁄ MIC ratio of 17.9 for tigecycline [39] . This pharmacodynamic measure was validated in a pulmonary pharmacokinetic study by Conte et al. [40] , which demonstrated therapeutically favourable C max ⁄ MIC 90 and AUC ⁄ MIC 90 ratios for tigecycline activity against Streptococcus pneumoniae, Chlamydia pneumoniae, Mycoplasma pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. Time above the MIC 90 was 100% for all five of these respiratory pathogens. The tigecycline AUC 0-12 h (134 mg h ⁄ L) in alveolar cells was approximately 78-fold higher than the AUC 0-12 h in serum, and the AUC 0-12 h (2.28 mg h ⁄ L) in epithelial lining fluid was approximately 32% higher than the AUC 0-12 h in serum.
Clinical trial data for complicated skin and soft tissue infections and for complicated intra-abdominal infections
In clinical studies, tigecycline has a demonstrated efficacy profile in the treatment of both complicated skin and soft tissue infections (cSSTIs) and complicated intra-abdominal infections (cIAIs) [21, 25, 26, 28] . Tigecycline has been evaluated in four large phase 3, double-blind, randomized, multicentre, active-comparator clinical studies in hospitalized patients with cSSTI or cIAI, in which it was not inferior at the 15% level (cure vs. failure) at test-of-cure assessments in either the cSSTI studies (p <0.0001) or the cIAI studies (p <0.0001). Fig. 4 summarizes the clinical cure rates for each of the two pooled study pairs. In the cSSTI studies used for drug approval, similar clinical cure rates were obtained with tigecycline and vancomycin-aztreonam (87% vs. 89%); rates were also similar for patients with monomicrobial [26] . and polymicrobial infections [26] . Fig. 5 presents the study design and disposition for this pooled analysis. Tigecycline monotherapy was shown to be as effective as vancomycin-aztreonam for treating cSSTIs. Cure rates with respect to pathogens were similar for the two treatment groups (e.g. 78% vs. 76% for MRSA), and noninferiority was demonstrated in all treatment subsets. Fig. 6 summarizes the results from the microbiologically evaluable populations in these studies [26] .
In the cIAI studies used for drug approval, tigecycline gave clinical cure rates similar to imipenem (each 86%), and rates were also similar for patients with monomicrobial and polymicrobial infections. Fig. 7 presents the study design and disposition for this pooled analysis. Tigecycline monotherapy was shown to be as effective as imipenem-cilastatin for treating cIAIs [25] . Cure rates according to diagnosis were also similar for the two treatment groups (e.g. 88% vs. 89% for complicated appendicitis), and noninferiority was demonstrated in all treatment subsets. Fig. 8 summarizes the results from the microbiologically evaluable populations in these studies.
Summary of tigecycline safety data in phase 3 cSSTI and cIAI studies
On the basis of 1415 tigecycline-treated and 1382 comparator-treated patients, nausea, vomiting and hyperbilirubinaemia were reported as adverse events significantly more often with tigecycline than with the comparator agents: 29.5% vs. 15.8%, 19.7% vs. 10.8%, and 2.3% vs. 0.9%, respectively [32, 33] . Most cases of nausea and vomiting were mild to moderate, and treatment discontinuation rates due to adverse events were similar between tigecycline and comparator treatment groups for cSSTIs (20 (3.5%) for tigecycline; 29 (5.3%) for vancomycin-aztreonam (p 0.188)) [26] and for cIAIs (21 (2.6%) for tigecycline; 12 (1.5%) for imipenem-cilastatin (p 0.116)) [25] . Table 7 summarizes commonly reported adverse events at the test-of-cure visit in these tigecycline phase 3 studies.
B E N E F I T S O F S I N G L E V S . M U L T I P L E A G E N T S
As the provision of healthcare becomes ever more complex, the administration of a single agent becomes more attractive, even if it is a new, potent antibiotic that historically might have been reserved in order to prevent the development of resistance to the new compound. At the current stage of emerging resistance, it is important to reconsider entrenched habits and assess whether simplified forms of antimicrobial stewardship will improve the treatment of infectious diseases. An additional argument in favour of monotherapy, considering also that reduced antibiotic use should result in reduced antimicrobial resistance, is the lower risk of toxicity and therapy-related adverse events when only a single agent is prescribed.
C O N C L U S I O N
Resistance to virtually all classes of antimicrobial agents is increasing, which highlights the fact that past practices during the last half-century and beyond have not been sufficient to prevent the development and spread of resistant pathogens. The inescapable conclusion from history is that Fig. 8 . Cure rates by diagnosis in the microbiologically evaluable population of the complicated intra-abdominal infection studies (tigecycline vs. imipenem-cilastatin) Adapted from reference [25] .
emerging resistance is intrinsic to antibacterial therapy itself, and that treatment, in the long term, leads to resistance in the very pathogens that it is intended to eradicate [17] . New strategies to slow the emergence of resistance require a paradigm shift in our use of antimicrobial agents. Increasing worldwide resistance in key pathogens (MRSA, enterococci, and enteric Gram-negative organisms) requires a reassessment of how we make the initial choice of treatment for likely infection, whenever the offending pathogen will remain unknown for several days. For example, rising MRSA infection rates will lead to an increased use of combination therapy unless monotherapy with a suitable agent is adopted. Data from many published studies argue that, as a general rule, combination therapy offers no advantage over monotherapy with an antimicrobial agent with a suitable spectrum of activity [5, 13, [41] [42] [43] . Although exclusive use of monotherapy is a clinically unrealistic objective, expanded prescription of a single agent, wherever it is likely to provide effective treatment, can lower the pressure for further development of resistant pathogens, and help to maintain the therapeutic foothold against an ever-worsening global problem concerning both community and healthcareassociated resistant bacterial infections.
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Common treatment all-cause adverse events (AEs) in phase 3 studies of tigecycline for complicated skin and soft tissue infections (cSSTIs) and complicated intra-abdominal infections (cIAIs) ALT, alanine aminotransferase; AST, aspartate aminotransferase. Adapted from references [25, 26] .
